NTT-DOCOMO
20.1.2023 09:01:39 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will organize a full-scale booth at MWC Barcelona 2023, the world’s largest mobile-related exhibition, in Barcelona, Spain from February 27 to March 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230120005094/en/
NTT DOCOMO Booth at MWC Barcelona 2023 (Graphic: Business Wire)
The DOCOMO booth, which will showcase exhibitions and presentations focused on the main themes of 6G, open radio access networks (Open RAN) and extended reality (XR), will also promote international standardization and global business for next-generation communication technologies. Due to the global pandemic, this will be DOCOMO’s the first onsite appearance at MWC Barcelona since 2019.1
In the 6G section, DOCOMO will present the coming 6G world and advanced wireless technologies that the company is currently developing. This will include a demonstration of the Human Augmentation Platform to communicate haptic sensations between people connected to a 6G network to enable, for example, a musical student to mimic the exact finger motions of a teacher.
In the Open RAN section, DOCOMO will present experiential content to help visitors understand the concept and structure of Open RAN, as well as progress being achieved to enable multi-vendor telecommunication equipment2 to be combined in Open RAN, as well as related collaborations with international carriers.
In the XR section, visitors will experience the metaverse filled with music, anime and movies and also a virtual-live system, both provided by NTT QONOQ, INC., a company launched by DOCOMO’s parent NTT group last October to promote XR business.
Through this exhibition, DOCOMO looks forward to globally communicating its advanced technologies and businesses under the company’s brand slogan “changing worlds with you.”
For more about DOCOMO’s exhibits and the overall exhibition, please refer to the appendix.
1 DOCOMO organized an exhibition in Japan in 2021 and then one online in 2022.
2 Creation of 5G Open RAN Ecosystem to Accelerate Adoption of Open RAN by Operators Globally”
https://www.docomo.ne.jp/english/info/media_center/pr/2021/0208_00.html
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2023
1. Exhibitions
Theme |
Exhibits |
Contents |
6G |
Human Augmentation Platform |
As an example of this 6G application, presenters will use haptic information to teach musical techniques and guide a robot in whisking green tea. |
Wireless Technologies |
DOCOMO’s technical approaches to the realization of 6G will be introduced with detailed explanations. |
|
Open RAN |
Interactive Contents |
Experiential content in the form of a simulation game will allow visitors to grasp the overview and structure of Open RAN. |
Shared Open Lab
|
This Open RAN verification facility located at the DOCOMO R&D Center in Japan will be introduced in 3D. |
|
XR |
XR World |
This metaverse diorama will enable people to view a life-size Godzilla from various angles. |
Matrix Stream |
Presenting NTT QONOQ’s virtual-live and general-purpose video-delivery system for extended reality |
|
Mixed Reality Animals—Volumetric Video × Magic Leap 2 |
Videos of real cats and penguins will be converted to 3DCG and projected into real space using a Magic Leap 2 MR headset. |
2. NTT DOCOMO Booth Location
4E50, Hall 4
3. Presentations
1 |
Broadcast Stage
|
2 |
5G Futures Summit
|
Note: The content and schedule of the presentations are subject to change. Please check the official website of MWC Barcelona 2023 for the latest information.
Reference
MWC Barcelona 2023
1. Dates & Times
Monday, February 27 to Thursday, March 2
08:30 to 19:00, except last day from 08:30 to 16:00 (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
3. Official Website
https://www.mwcbarcelona.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230120005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom